Skip to main content
ChenDermatologist
ChenDermatologist
Dr. Chen Yi-Jia · Dermatology Notes
English version. Prefer Traditional Chinese? Switch to Chinese
Patient education · AD / Systemic Per AAD 2024 + 2023 + UpToDate 2024 · Updated 2026-05-09

Systemic therapy for atopic dermatitis
Biologics, JAK inhibitors, phototherapy compared

When AD remains moderate-severe (EASI ≥ 16, IGA ≥ 3) or significantly impacts sleep/work after 4-8 weeks of adequate topical care, step up to systemic therapy. AAD 2024 update (Davis): (1) Biologics — dupilumab/Dupixent® (best long-term safety), tralokinumab, lebrikizumab, nemolizumab (best itch reduction); (2) Oral JAK inhibitors — abrocitinib, upadacitinib (fastest, highest clearance, but FDA black-box warning); (3) NB-UVB phototherapy (alternative when biologics/JAKi unavailable). This article includes a detailed comparison chart.

Note: All systemic AD therapies require specialist evaluation, baseline screening, and ongoing monitoring (LFT, renal, TB, infection, CV events, malignancy). JAK inhibitors carry FDA black-box warnings (MACE, VTE, malignancy, serious infection) — avoid in age ≥ 65, smokers, prior CV/VTE/cancer. Patient education only.
Key Fact (Davis 2024, JAAD update · Davis 2024, JAAD photo+systemic)

Dupilumab launched the AD precision-medicine era in 2017. Before that, moderate-to-severe AD could only rely on cyclosporine (short-term) or struggle with topicals. Today 4 biologics + 3 JAK inhibitors achieve EASI 75 in 60–78% without routine blood monitoring. Taiwan NHI has provided conditional coverage for dupilumab since 2021 for EASI ≥ 24 + IGA 4 + prior-treatment failure. Newer drugs (lebrikizumab, nemolizumab, JAKi) are mostly out-of-pocket with annual costs of NT$ 350,000–650,000.

When to step up to systemic therapy

EASI ≥ 16 or IGA ≥ 3, BSA ≥ 10% with ≥ 3 nights/week sleep disturbance, DLQI ≥ 11 or POEM ≥ 17, or 4-8 weeks of adequate topical care without control.

Phototherapy

NB-UVB (311 nm) 2-3×/week × 12-24 weeks; EASI 50 ~ 50-60%. Pregnancy-safe. UVA1 for acute exudative AD (limited Taiwan availability). PUVA largely retired.

Biologics (subcutaneous, best safety)

  • Dupilumab (anti-IL-4Rα): every 2 weeks SC, EASI 75 ~51%, ≥ 6 months age, FDA 2017, conjunctivitis 8-15%. Taiwan NHI-covered (EASI ≥ 24, IGA ≥ 4, prior failures).
  • Tralokinumab (anti-IL-13): every 2 weeks SC, EASI 75 ~33%, ≥ 12 y.
  • Lebrikizumab (anti-IL-13, newer): every 4 weeks SC maintenance, EASI 75 ~53%, FDA 2024 ≥ 12 y.
  • Nemolizumab (anti-IL-31R): every 4 weeks SC, itch reduction ~70% (highest), EASI 75 ~36%, FDA 2024 ≥ 12 y.

JAK inhibitors (oral, fastest, FDA black-box)

  • Upadacitinib (JAK1) 15-30 mg/day, EASI 75 up to 78% (highest), ≥ 12 y. Onset 1-2 weeks.
  • Abrocitinib (JAK1) 100-200 mg/day, EASI 75 ~60-73%, ≥ 12 y.
  • Baricitinib (JAK1/2): EU and Japan approved for AD; not FDA-approved for AD. EASI 75 ~25-30%.

Black-box: MACE, VTE, lymphoma, serious infections. Avoid age ≥ 65, smokers, prior CV/VTE/malignancy.

Traditional immunosuppressants

Cyclosporine 2.5-5 mg/kg/day (≤ 1 year, fast acting); methotrexate 10-25 mg/week; azathioprine 1-3 mg/kg/day (check TPMT); mycophenolate 2-3 g/day. Systemic steroids only as short-term bridge.

Decision framework

Highest clearance and oral preference → upadacitinib 30 mg. Best long-term safety, no labs → dupilumab. Itch-dominant → nemolizumab. Failed dupilumab → lebrikizumab. Cannot use biologic/JAKi → NB-UVB + cyclosporine bridge.

Bottom line

Modern AD treatment offers 4 biologics + 3 JAKi reaching EASI 75 in 33-78% of patients. Dupilumab remains the safest first-line; upadacitinib provides the fastest, deepest clearance with black-box trade-off; nemolizumab uniquely targets itch. Discuss with your dermatologist based on goals, safety profile, convenience, and cost.